DRMA · Dermata Therapeutics, Inc. · Debt
$1.13
+0.02 (+1.80%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the financial statements, which is not alleviated by management's plans.”View the 10-Q filed Aug 11, 2026
Market Cap
$4.58M
Shares
4.02M
Volume · Oct 5
14.16K
Avg daily vol (3M)
700.21K
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of long-term debt | 2021-12-31 | USD 0 | 10-K filed 2022-03-28 |
| Noncurrent convertible notes payable | 2021-12-31 | USD 0 | 10-K filed 2022-03-28 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.